Breaking World Pharma News

AI tailors artificial DNA for future drug development

With the help of an AI, researchers at Chalmers University of Technology, Sweden, have succeeded in designing synthetic DNA that controls the cells' protein production. The technology can contribute to the development and production of vaccines, drugs for severe diseases, as well as alternative food proteins much faster and at significantly lower costs than today.

Remdesivir reduces COVID-19 mortality in a real-world setting

The COVID-19 pandemic has led to an explosion of clinical research resulting in the development of a variety of vaccines and treatments, although the efficacy of some remains controversial. Now, researchers from Japan report that remdesivir, a drug whose effectiveness has been debated, appears to make a big difference in Japanese patients with COVID-19 who received corticosteroids in the ICU.

Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an analysis examining the immune response induced by their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine [Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)] against newer Omicron sublineages, including BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1.

Pocket feature shared by deadly coronaviruses could lead to pan-coronavirus antiviral treatment

Scientists have discovered why some coronaviruses are more likely to cause severe disease, which has remained a mystery, until now. Researchers of the University of Bristol-led study, published in Science Advances today, say their findings could lead to the development of a pan-coronavirus treatment to defeat all coronaviruses - from the 2002 SARS-CoV outbreak to Omicron, the current variant of SARS-CoV-2, as well as dangerous variants that may emerge in future.

FDA approves first gene therapy to treat adults with Hemophilia B

Today, the U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Cryptic drug-binding sites discovered in the dance

Some of the toughest challenges in treating disease are presented by “undruggable” proteins whose structures and roles in disease are known but are seemingly unable to be targeted by drugs that will bind to them. Researchers at King Abdullah University of Science and Technology (KAUST) have now shown that the molecular motion of many "undruggable" proteins can in fact expose sites at which drugs could bind.

Unusual type of antibody shows ultrapotent activity against Zika

An unusual type of antibody that even at miniscule levels neutralizes the Zika virus and renders the virus infection undetectable in preclinical models has been identified by a team led by Weill Cornell Medicine, NewYork-Presbyterian and National Institutes of Health (NIH) investigators.

GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well tolerated and showed early bactericidal activity with a low, once-daily oral dose after 14 days of treatment in participants with drug-susceptible pulmonary tuberculosis.

Machine learning can help predict patient response to cancer immunotherapy

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy are one step closer to solving that problem.

Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by the European Commission, as a booster for the prevention of COVID-19 in adults 18 years of age and older.

WORLDPHARMANEWS

Breaking World Pharma News

AI tailors artificial DNA for future drug development

Remdesivir reduces COVID-19 mortality in a real-world setting

Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster

Pocket feature shared by deadly coronaviruses could lead to pan-coronavirus antiviral treatment

FDA approves first gene therapy to treat adults with Hemophilia B

Cryptic drug-binding sites discovered in the dance

Unusual type of antibody shows ultrapotent activity against Zika

GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis

Machine learning can help predict patient response to cancer immunotherapy

Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs